TCR CURE Biopharma Technology Co., Ltd.

TCR CURE Biopharma Technology Co., Ltd. (天科雅) is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, focused on the innovation, development and clinical translation of cellular immunotherapy for solid tumors. According to its corporate profile, the company is advancing eight R&D pipelines built on multiple proprietary cell-engineering platform technologies, exploring immune-cell therapy across a range of cancer types. The company's product pipelines target several tumor-associated antigens, including ALPP, IL-13Rα2, GPC3, DLL3, NY-ESO-1 and LMP2, which are highly expressed in solid tumors such as ovarian cancer, endometrial cancer, glioblastoma, liver cancer, lung cancer, sarcoma and nasopharyngeal carcinoma. To address the specific challenges of cell-therapy development, TCRCure has built an integrated development system covering the full lifecycle of candidate products — from research and manufacturing to clinical translation — using modular workflows combined with its proprietary technology platforms to enable rapid iteration and optimization of CAR-T and TCR-T candidates. TCRCure's technology stack includes the ASPIRE-T platform, described as a next-generation T-cell therapy platform that redirects the TCR/CD3 complex to overcome key limitations of conventional CAR-T and TCR-T therapies; the ARMORS platform, an advanced cell-armoring platform designed to help adoptive cell therapies (ACT) break through the tumor microenvironment (TME) barrier and heterogeneity; the TRUST platform, an AI-driven high-throughput platform combining single-cell transcriptomics and functional analysis to rapidly discover therapeutic TCR clones; and an industrial clinical-grade vector and engineered immune-cell manufacturing platform. The company operates R&D centers and production facilities in both China and the United States, with locations cited in Guangzhou, Hong Kong and Los Angeles. Its stated mission is to make cancer a controllable disease and ultimately to cure it, and its stated ambition is to become one of the global leaders in cellular immunotherapy. TCRCure has received recognition including inclusion in the 2024 Hurun Global Cheetahs Index and designation as a "specialized, refined, distinctive and innovative" (专精特新) SME in Guangdong Province.

TCRCure's corporate history, as presented on its own website, begins in November 2016 with the establishment of Chongqing TCRCure (重庆天科雅). The company subsequently expanded through a series of entity formations: in January 2019 Guangdong TCRCure (广东天科雅) was established; in December 2019 IMMCURE Limited and TCRCure (BVI) were formed; in February 2020 Hong Kong TCRCure was established; in December 2020 TCRCure Biopharma (天科雅生物) was founded; in September 2021 Tianjin TCRCure was established; and in May 2025 Beijing Cell Technology (北京细胞科技) was established. This sequence reflects a strategy of building a multi-entity group spanning mainland China, Hong Kong and offshore jurisdictions to support R&D, manufacturing and clinical development. From its founding, TCRCure has focused on cellular immunotherapy for solid tumors — a field in which cell therapies such as CAR-T have shown revolutionary and potentially curative results in hematological malignancies but face substantial barriers in solid tumors. The company states that it has built an integrated development system covering the full lifecycle of candidate products, from research and manufacturing to clinical translation, and that it operates R&D centers and production facilities in both China and the United States, with locations cited in Guangzhou, Hong Kong and Los Angeles. By the early 2020s TCRCure was advancing eight R&D pipelines targeting tumor-associated antigens including ALPP, IL-13Rα2, GPC3, DLL3, NY-ESO-1 and LMP2, across cancers such as ovarian cancer, endometrial cancer, glioblastoma, liver cancer, lung cancer, sarcoma and nasopharyngeal carcinoma. The company presented solid-tumor research at the ESMO 2022 congress and at the 37th SITC Annual Meeting in 2022, including what it described as the first CAR-T cell immunotherapy for pan-gynecological tumors. It has also received external recognition, including inclusion in the 2024 Hurun Global Cheetahs Index and designation as a Guangdong 'specialized, refined, distinctive and innovative' SME in 2024, and was listed on Guangzhou's Future Unicorn innovative enterprise list in 2023.

• Chongqing TCRCure established.

• Guangdong TCRCure established.

• IMMCURE Limited and TCRCure (BVI) established.

• Hong Kong TCRCure established.

• TCRCure Biopharma established.

• Tianjin TCRCure established.

• Solid-tumor clinical research presented at ESMO 2022.

• Solid-tumor R&D results presented at the 37th SITC Annual Meeting.

• Listed on the 2023 Guangzhou Future Unicorn innovative enterprise list.

• Recognized as a Guangdong 'specialized, refined, distinctive and innovative' SME.

• Named to the 2024 Hurun Global Cheetahs Index.

• Beijing Cell Technology established.

Clinical-stage cellular immunotherapy developer targeting solid tumors, positioning itself as a potential global leader in cell immunotherapy.

• ASPIRE-T platform

  Next-generation T-cell therapy platform that redirects the TCR/CD3 complex to overcome key limitations of conventional CAR-T and TCR-T therapies, aiming for potent, durable and safer immune responses against solid tumors.

• ARMORS platform

  Advanced cell-armoring platform that equips adoptive cell therapies (ACT) to break through the tumor microenvironment (TME) barrier and heterogeneity, improving safety, infiltration and persistence in solid-tumor treatment.

• TRUST platform

  AI-driven high-throughput platform combining single-cell transcriptomics and functional analysis to rapidly discover therapeutic TCR clones, shortening TCR drug development cycles and reducing costs.

• Industrial clinical-grade vector and engineered immune cell manufacturing platform

  Industrial clinical-grade production of vectors and engineered immune cells, forming the foundation of the company's clinical development capability in immune cell therapy.

• CAR-T and TCR-T candidate pipelines

  Eight R&D pipelines targeting tumor-associated antigens including ALPP, IL-13Rα2, GPC3, DLL3, NY-ESO-1 and LMP2 across multiple solid tumors.

1. 1天科雅官方网站首页tcrcure.com
2. 2天科雅发展历程tcrcure.com
3. 3天科雅企业简介tcrcure.com
4. 4天科雅企业简介tcrcure.com
5. 5Wikidata: TCR CURE Biopharma Technology Co., Ltd. (China)wikidata.org